Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real-world Implications

समान संसाधन

• JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
  द्वारा: Prithviraj Bose, और अन्य
  प्रकाशित: (2020-08-01)
• P1044: REDUCTION IN RED BLOOD CELL TRANSFUSION BURDEN: A NOVEL LONGITUDINAL TIME-DEPENDENT ANALYSIS IN PATIENTS WITH TRANSFUSION-DEPENDENT MYELOFIBROSIS TREATED WITH MOMELOTINIB
  द्वारा: Claire Harrison, और अन्य
  प्रकाशित: (2023-08-01)
• S195: MOMENTUM: PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) IN SYMPTOMATIC AND ANEMIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR
  द्वारा: S. Verstovsek, और अन्य
  प्रकाशित: (2022-06-01)
• MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
  द्वारा: Verstovsek, S, और अन्य
  प्रकाशित: (2021)
• Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study
  द्वारा: Ruben A. Mesa, और अन्य
  प्रकाशित: (2023-11-01)